5 Stocks Pushing The Health Services Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 116 points (0.8%) at 15,038 as of Monday, Sept. 9, 2013, 12:44 PM ET. The NYSE advances/declines ratio sits at 2,262 issues advancing vs. 646 declining with 106 unchanged.

The Health Services industry currently sits up 0.3% versus the S&P 500, which is up 0.7%. On the negative front, top decliners within the industry include Tenet Healthcare ( THC), down 4.4%, and Catamaran ( CTRX), down 1.4%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Align Technology ( ALGN) is one of the companies pushing the Health Services industry higher today. As of noon trading, Align Technology is up $1.38 (3.1%) to $46.23 on light volume. Thus far, 201,743 shares of Align Technology exchanged hands as compared to its average daily volume of 622,800 shares. The stock has ranged in price between $44.98-$46.24 after having opened the day at $45.03 as compared to the previous trading day's close of $44.85.

Align Technology, Inc. operates as a medical device company primarily in the United States and internationally. Align Technology has a market cap of $3.6 billion and is part of the health care sector. Shares are up 61.6% year to date as of the close of trading on Friday. Currently there are 6 analysts that rate Align Technology a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Align Technology as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Align Technology Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, ResMed ( RMD) is up $1.39 (2.8%) to $50.54 on light volume. Thus far, 377,983 shares of ResMed exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $49.34-$50.54 after having opened the day at $49.38 as compared to the previous trading day's close of $49.15.

ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. ResMed has a market cap of $7.0 billion and is part of the health care sector. Shares are up 18.2% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate ResMed a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full ResMed Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Agilent Technologies ( A) is up $0.38 (0.8%) to $47.81 on light volume. Thus far, 897,489 shares of Agilent Technologies exchanged hands as compared to its average daily volume of 2.6 million shares. The stock has ranged in price between $47.29-$47.90 after having opened the day at $47.49 as compared to the previous trading day's close of $47.43.

Agilent Technologies is on the leading edge of nearly every major trend in communications and life sciences. From optical and wireless communications to disease and discovery research, Agilent delivers product and technology innovations that benefit millions of people around the world. Agilent Technologies has a market cap of $16.4 billion and is part of the health care sector. Shares are up 15.9% year to date as of the close of trading on Friday. Currently there are 13 analysts that rate Agilent Technologies a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Agilent Technologies as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, reasonable valuation levels, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Agilent Technologies Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Thermo Fisher Scientific ( TMO) is up $0.60 (0.7%) to $91.12 on light volume. Thus far, 436,875 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $90.72-$91.50 after having opened the day at $90.80 as compared to the previous trading day's close of $90.51.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Thermo Fisher Scientific has a market cap of $32.7 billion and is part of the health care sector. Shares are up 41.9% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Thermo Fisher Scientific Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Boston Scientific ( BSX) is up $0.42 (3.6%) to $11.92 on heavy volume. Thus far, 12.2 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 15.9 million shares. The stock has ranged in price between $11.46-$11.92 after having opened the day at $11.51 as compared to the previous trading day's close of $11.50.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Boston Scientific has a market cap of $15.5 billion and is part of the health care sector. Shares are up 100.7% year to date as of the close of trading on Friday. Currently there are 4 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 14 rate it a hold.

TheStreet Ratings rates Boston Scientific as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, solid stock price performance, expanding profit margins, impressive record of earnings per share growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Boston Scientific Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).
null